secwatch.observer — SEC 8-K summary
======================================

Issuer:     INSMED Inc (INSM)
CIK:        0001104506
Form:       8-K
Filed at:   2025-12-17T23:59:59+00:00
Accession:  0001140361-25-045836
Event type: other_material
Sentiment:  negative
Materiality: 0.80
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Insmed brensocatib fails Phase 2b CRSsNP; acquires INS1148 antibody
-------------------------------------------------------------------

- Phase 2b BiRCh study missed primary endpoint: placebo LS mean -2.44, brensocatib 10mg -2.21, 40mg -2.33.
- All secondary endpoints also not met; Insmed discontinues CRSsNP program immediately.
- Brensocatib well tolerated with no new safety signals; 40 mg dose had 69.9% TEAEs vs 65.3% placebo.
- Acquired INS1148 (anti-SCF248 mAb) from Opsidio; plans Phase 2 in interstitial lung disease and asthma.
- INS1148 targets only inflammatory c-Kit signaling, sparing homeostatic pathways, potentially first-in-class.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1104506/000114036125045836/0001140361-25-045836-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1104506/000114036125045836/ef20061465_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-25-045836

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer